Table 1. Patient Characteristics.
| Variables | Patients (N = 27) |
|---|---|
| Sex, male/female | 15 (55.6%)/12 (44.4%) |
| Age, years, median (IQR) | 44.0 (34.5 - 59.5) |
| Disease type | |
| Proctitis | 4 (14.8%) |
| Left-side colitis | 6 (22.2%) |
| Pancolitis | 17 (63.0%) |
| Current treatment | |
| 5-aminosalicylic acid | |
| Oral | 22 (81.5%) |
| Oral + topical | 1 (3.7%) |
| Corticosteroids | |
| Oral | 4 (14.8%) |
| Topical | 1 (3.7%) |
| Immunomodulators | |
| Azathioprine | 4 (14.8%) |
| 6-mercaptopurin | 1 (3.7%) |
| Biologics | |
| Infliximab | 1 (3.7%) |
| Adalimumab | 2 (7.4%) |
| Ustekinumab | 1 (3.7%) |
| Vedolizumab | 1 (3.7%) |
| Laboratory parameter | |
| Serum activin A, pg/mL, median (IQR) | 134.8 (105.3 - 188.1) |
| C-reactive protein, mg/dL, median (IQR) | 0.03 (0.02 - 0.09) |
| White blood cell count, /µL, median (IQR) | 4,700 (3,700 - 5,500) |
| Erythrocyte sedimentation rate, mm/h, median (IQR) | 3.0 (2.0 - 9.5) |
| Leucine-rich alpha-2 glycoprotein, µg/mL, median (IQR) | 10.8 (9.4 - 13.1) |
| Partial Mayo score, median (IQR) | 1 (0 - 1) |
| Mayo score, median (IQR) | 2 (1 - 3) |
| Mayo endoscopic subscore, median (IQR) | 1 (1 - 2) |
| Endoscopic healing/non-endoscopic healing | 5 (18.5%)/22 (81.5%) |
IQR: interquartile range.